Advertisement
Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice
Nadine Beetz,1 Michael D. Harrison,2,3 Marc Brede,4 Xiangang Zong,5 Michal J. Urbanski,1 Anika Sietmann,6 Jennifer Kaufling,7 Stefan Lorkowski,6 Michel Barrot,7 Mathias W. Seeliger,8 Maria Augusta Vieira-Coelho,9 Pavel Hamet,10,11 Daniel Gaudet,10,12 Ondrej Seda,11 Johanne Tremblay,10,11 Theodore A. Kotchen,13 Mary Kaldunski,3 Rolf Nüsing,14 Bela Szabo,1 Howard J. Jacob,2,3 Allen W. Cowley Jr.,3 Martin Biel,5 Monika Stoll,6 Martin J. Lohse,4 Ulrich Broeckel,2,3,13,15 and Lutz Hein1
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Beetz, N. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Harrison, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Brede, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Zong, X. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Urbanski, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Sietmann, A. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Kaufling, J. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Lorkowski, S. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Barrot, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Seeliger, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Vieira-Coelho, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Hamet, P. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Gaudet, D. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Seda, O. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Tremblay, J. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Kotchen, T. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Kaldunski, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Nüsing, R. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Szabo, B. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Jacob, H. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Cowley, A. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Biel, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Stoll, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Lohse, M. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Broeckel, U. in: JCI | PubMed | Google Scholar
1Institute of Experimental and Clinical Pharmacology and Toxicology and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany. 2Human and Molecular Genetics Center and 3Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 4Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 5Department of Pharmacy, Center for Drug Research, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-University, München, Germany. 6Leibniz Institute for Arteriosclerosis Research, University of Münster, Münster, Germany. 7Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France. 8Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Centre for Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Germany. 9Institute of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. 10University of Montreal, Montréal, Quebec, Canada. 11Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada. 12Chicoutimi Hospital, Chicoutimi, Quebec, Canada. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 14Institute of Clinical Pharmacology, University of Frankfurt, Frankfurt, Germany. 15Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Find articles by Hein, L. in: JCI | PubMed | Google Scholar
Published December 22, 2010 - More info
J Clin Invest. 2011;121(1):454–454. https://doi.org/10.1172/JCI45819.
© 2010 The American Society for Clinical Investigation
Related article:
Abstract
Hypertension and its complications represent leading causes of morbidity and mortality. Although the cause of hypertension is unknown in most patients, genetic factors are recognized as contributing significantly to an individual’s lifetime risk of developing the condition. Here, we investigated the role of the G protein regulator phosducin (Pdc) in hypertension. Mice with a targeted deletion of the gene encoding Pdc (Pdc–/– mice) had increased blood pressure despite normal cardiac function and vascular reactivity, and displayed elevated catecholamine turnover in the peripheral sympathetic system. Isolated postganglionic sympathetic neurons from Pdc–/– mice showed prolonged action potential firing after stimulation with acetylcholine and increased firing frequencies during membrane depolarization. Furthermore, Pdc–/– mice displayed exaggerated increases in blood pressure in response to post-operative stress. Candidate gene–based association studies in 2 different human populations revealed several SNPs in the PDC gene to be associated with stress-dependent blood pressure phenotypes. Individuals homozygous for the G allele of an intronic PDC SNP (rs12402521) had 12–15 mmHg higher blood pressure than those carrying the A allele. These findings demonstrate that PDC is an important modulator of sympathetic activity and blood pressure and may thus represent a promising target for treatment of stress-dependent hypertension.
Authors
Nadine Beetz, Michael D. Harrison, Marc Brede, Xiangang Zong, Michal J. Urbanski, Anika Sietmann, Jennifer Kaufling, Michel Barrot, Mathias W. Seeliger, Maria Augusta Vieira-Coelho, Pavel Hamet, Daniel Gaudet, Ondrej Seda, Johanne Tremblay, Theodore A. Kotchen, Mary Kaldunski, Rolf Nüsing, Bela Szabo, Howard J. Jacob, Allen W. Cowley Jr., Martin Biel, Monika Stoll, Martin J. Lohse, Ulrich Broeckel, Lutz Hein
Original citation: J Clin Invest.2009;119(12):3597–3612. doi:10.1172/JCI38433.
Citation for this corrigendum: J Clin Invest. 2011;121(1):454. doi:10.1172/JCI45819.
Stefan Lorkowski was inadvertently omitted from the author list. The correct author list and affiliations appear above.
The authors regret the error.
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)